Literature DB >> 17490879

1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies.

Yunsong Tong1, Akiyo Claiborne, Magdalena Pyzytulinska, Zhi-Fu Tao, Kent D Stewart, Peter Kovar, Zehan Chen, Robert B Credo, Ran Guan, Philip J Merta, Haiying Zhang, Jennifer Bouska, Elizabeth A Everitt, Bernard P Murry, Dean Hickman, Tim J Stratton, Jian Wu, Saul H Rosenberg, Hing L Sham, Thomas J Sowin, Nan-horng Lin.   

Abstract

A study on substitutions at the four open positions on the phenyl ring of the 1,4-dihydroindeno[1,2-c]pyrazoles as potent CHK-1 inhibitors is described. Bis-substitution at both the 6- and 7-positions led to inhibitors with IC(50) values below 0.3nM. The compound with the best overall activities (36) was able to potentiate the anti-proliferative effect of doxorubicin in HeLa cells by at least 47-fold. Physicochemical, metabolic, and pharmacokinetic properties of selected inhibitors are also disclosed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490879     DOI: 10.1016/j.bmcl.2007.04.055

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.

Authors:  Xiu-Mei Chen; Tao Lu; Shuai Lu; Hui-Fang Li; Hao-Liang Yuan; Ting Ran; Hai-Chun Liu; Ya-Dong Chen
Journal:  J Mol Model       Date:  2009-12-18       Impact factor: 1.810

Review 2.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.

Authors:  Cyril Ronco; Anthony R Martin; Luc Demange; Rachid Benhida
Journal:  Medchemcomm       Date:  2016-11-30       Impact factor: 3.597

3.  Synthesis and Cytotoxic Activity of Novel Tetrahydrocurcumin Derivatives Bearing Pyrazole Moiety.

Authors:  Ahmed Mahal; Ping Wu; Zi-Hua Jiang; Xiaoyi Wei
Journal:  Nat Prod Bioprospect       Date:  2017-11-01

4.  A New Series of Indeno[1,2-c]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy.

Authors:  Ahmet Özdemir; Halilibrahim Ciftci; Belgin Sever; Hiroshi Tateishi; Masami Otsuka; Mikako Fujita; Mehlika Dilek Altıntop
Journal:  Molecules       Date:  2022-01-13       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.